moatshark My

All holdings

Repligen Ord

RGEN

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$5.6m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Fund portfolios
1
Funds holding it
See which
Price at Q2 ’26 end
$136.44
+15.8% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+18.1%Q3 ’24
-3.3%Q4 ’24
-11.6%Q1 ’25
-2.2%Q2 ’25
+15.8%Q2 ’26
Q3 ’24: +18.1%; Q4 ’24: -3.3%; Q1 ’25: -11.6%; Q2 ’25: -2.2%; Q2 ’26: +15.8%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
0Q3 ’25
0Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 0; Q4 ’25: 0; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Repligen Ord.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Repligen Ord
Weitz Investment Management0.4%$5.6m$5.6mAdded +60%2 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Repligen Ord
Bought or soldFiling
5 Oct 2026Loeillot OlivierChief Executive Officer▼ Sold4,202$190.00$798kForm 4
5 Oct 2026Loeillot OlivierChief Executive Officer▼ Sold1,333$178.75$238kForm 4
24 Sep 2026Loeillot OlivierChief Executive Officer▼ Sold8,404$190.00$1.6mForm 4
24 Sep 2026Loeillot OlivierChief Executive Officer▼ Sold4,542$190.00$863kForm 4
21 Sep 2026Loeillot OlivierChief Executive Officer▼ Sold5,426$180.00$977kForm 4
4 Sep 2026Loeillot OlivierChief Executive Officer▼ Sold3,035$165.90$504kForm 4
20 Aug 2026Loeillot OlivierChief Executive Officer▼ Sold5,426$180.00$977kForm 4
16 Jul 2026Garland Jason KCFO▼ Sold530$150.00$80kForm 4

About the company

Sector
Health care · Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
56m at 24 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$68.2m2013
$83.5m2015
$141m2017
2019
2021
2023
2025
2013: $68.2m; 2014: $63.5m; 2015: $83.5m; 2016: $105m; 2017: $141m; 2018: not held; 2019: not held; 2020: not held; 2021: not held; 2022: not held; 2023: not held; 2024: not held; 2025: not held
Repligen Ord revenue and net income by year
YearRevenueNet income
2025–$48.9m
2024–−$25.5m
2023–$35.6m
2022–$186m
2021–$128m
2020–$59.9m
2019–$21.4m
2018–$16.6m
2017$141m$28.4m
2016$105m$11.7m
2015$83.5m$9.3m
2014$63.5m$8.2m
2013$68.2m$16.1m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Repligen Ord, from their latest N-PORT filings.

Funds holding Repligen Ord
Weitz Partners Value FundWeitz Investment Management1.1%$5.5m30 Jun 2026